Fennec Pharmaceuticals

Fennec Pharmaceuticals

FENC· Manufacturing· Fiscal year ends in December

CEO pay in FY2024Stock -43.7% in FY2024

Jeff Hackman is the CEO of Fennec Pharmaceuticals and was paid $1.6M in FY2024 (Dec).

Pay$100 in the stock at the end of FY22 → $66
CEO pay is from each Fennec Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Jeff HackmanFY2024
  2. 2Pierre Sayad, CMOFY2024
  3. 3Robert AndradeFY2022

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Fennec Pharmaceuticals paid its 2 named executives $2.1M in total in FY2024 (Dec). CEO Jeff Hackman was paid $1.6M of that.

Name
Jeff HackmanCEONot disclosed
Pierre Sayad, CMONot disclosed
Robert AndradeCFONot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Fennec Pharmaceuticals. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board4

See all
  • Khalid Islam, Ph.D.Chair · 11 yr on the boardIndependentAudit—Paid as an executive
  • Rostislav RaykovDirector · 16 yr on the boardIndependent—Paid as an executive
  • Marco BrugheraDirector · 9 yr on the boardIndependentAudit, Compensation (Chair), Governance and Nominating—Paid as an executive
  • Jodi CookDirector · 6 yr on the boardIndependentCompensation, Governance and Nominating (Chair)—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 28, 2026FY2025
Annual report10-KMar 27, 2026FY2025
Proxy statementDEF 14AApr 25, 2025FY2024
Annual report10-KMar 26, 2025FY2024
Proxy statementDEF 14AMay 13, 2024FY2023
Annual report10-KMar 29, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data